Document Detail


Cerebrospinal fluid biomarkers in the differential diagnosis of Alzheimer's disease from other cortical dementias.
MedLine Citation:
PMID:  20802215     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Considering that most semantic dementia (SD) and frontotemporal dementia (FTD) patients show no post-mortem Alzheimer's disease (AD) pathology, cerebrospinal fluid (CSF) biomarkers may be of value for distinguishing these patients from those with AD. Additionally, biomarkers may be useful for identifying patients with atypical phenotypic presentations of AD, such as posterior cortical atrophy (PCA) and primary progressive non-fluent or logopenic aphasia (PNFLA).
METHODS: The authors investigated CSF biomarkers (beta-amyloid 1-42 (Aβ(42)), total tau (T-tau) and phosphorylated tau (P-tau)) in 164 patients with AD (n=60), PCA (n=15), behavioural variant FTD (n=27), SD (n=19), PNFLA (n=26) and functional cognitive disorders (FCD, n=17). The authors then examined the diagnostic value of these CSF biomarkers in distinguishing these patients from those with AD.
RESULTS: The P-Tau/Aβ(42) ratio was found to be the best biomarker for distinguishing AD from FTD and SD, with a sensitivity of 91.7% and 98.3%, respectively, and a specificity of 92.6% and 84.2%, respectively. As expected, biomarkers were less effective in differentiating AD from PNFLA and PCA, as significant proportions of PCA and PNFLA patients (60% and 61.5%, respectively) had concurrent alterations of both T-tau/Aβ(42) and P-Tau/Aβ(42) ratios. None of the FCD patients had a typical AD CSF profile or abnormal T-tau/Aβ(42) or P-Tau/Aβ(42) ratios.
CONCLUSION: The P-Tau/Aβ(42) ratio is a useful tool to distinguish AD from both FTD and SD, which are known to involve pathological processes distinct from AD. Biomarkers could be useful for identifying patients with an atypical AD phenotype that includes PNFLA and PCA.
Authors:
Leonardo Cruz de Souza; Foudil Lamari; Serge Belliard; Claude Jardel; Caroline Houillier; Raphael De Paz; Bruno Dubois; Marie Sarazin
Related Documents :
8413945 - Nonoptic aphasia: aphasia with preserved confrontation naming in alzheimer's disease.
9635475 - Prevalence of dementia of alzheimer type and apolipoprotein e phenotypes in aged patien...
15374365 - Long-term idebenone treatment of vascular and degenerative brain disorders of the elderly.
17917455 - Positron emission tomography facilitates diagnosis of early-onset alzheimer's disease.
19591075 - Changes in amniotic fluid concentration of thrombin-antithrombin iii complexes in patie...
24179805 - Mri findings in aoa2: cerebellar atrophy and abnormal iron detection in dentate nucleus.
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-08-27
Journal Detail:
Title:  Journal of neurology, neurosurgery, and psychiatry     Volume:  82     ISSN:  1468-330X     ISO Abbreviation:  J. Neurol. Neurosurg. Psychiatr.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-02-17     Completed Date:  2011-04-04     Revised Date:  2011-05-11    
Medline Journal Info:
Nlm Unique ID:  2985191R     Medline TA:  J Neurol Neurosurg Psychiatry     Country:  England    
Other Details:
Languages:  eng     Pagination:  240-6     Citation Subset:  IM    
Affiliation:
CRICM, UPMC Univ Paris 06, Pitié-Salpêtrière Hospital, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Aged
Alzheimer Disease / cerebrospinal fluid*,  diagnosis
Amyloid beta-Peptides / cerebrospinal fluid
Aphasia, Primary Progressive / cerebrospinal fluid,  diagnosis
Atrophy
Biological Markers / cerebrospinal fluid
Cerebral Cortex / pathology
Cognition Disorders / cerebrospinal fluid,  diagnosis
Dementia / cerebrospinal fluid*,  diagnosis
Diagnosis, Differential
Female
Frontotemporal Dementia / cerebrospinal fluid,  diagnosis
Humans
Male
Middle Aged
Peptide Fragments / cerebrospinal fluid
Phosphorylation
tau Proteins / cerebrospinal fluid
Chemical
Reg. No./Substance:
0/Amyloid beta-Peptides; 0/Biological Markers; 0/Peptide Fragments; 0/amyloid beta-protein (1-42); 0/tau Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Impaired updating ability in drivers with Parkinson's disease.
Next Document:  Familial Alzheimer's disease and inherited prion disease in the UK are poorly ascertained.